Nippon India Nifty Pharma ETF
Ticker: PHARMABEES
Decent
48/100
☆ Add to Watchlist
Investing Reference
Price
22.05
Market Cap
45.06
Debt/Equity
ROE %
PB
Promoter %
Pledge %
1Y Rev Growth %
5Y Rev Growth %
NP Margin %
NP Margin 5Y Avg %
Trading Reference
1M Return %
-1.400
6M Return %
1.286
1Y Return %
-7.040
% Away 52W High
11.791
% Away 52W Low
13.251
Daily Volume
11939702
Investment Verdict
Avoid
Score 0/100 · Position size: 0%
Fundamentals/valuations or risk flags are weak. Avoid for long-term investing.
Trading Verdict
Avoid
Score 5/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
80%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
The Nippon India Nifty Pharma ETF is currently trading near a key support level, with the 50-day EMA indicating bullish momentum. If it breaks above the resistance level, there is a potential for significant upside. However, if it fails to hold the support, downside risks may increase.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
L
Lerthai Finance Ltd
Lerthai Finance Ltd presents several risks with limited growth prospects and profitability concerns, making it a risky investment.
View details
S
Shree Rajasthan Syntex Ltd
Shree Rajasthan Syntex Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
D
Danube Industries Ltd
Danube Industries Ltd shows potential but faces challenges in profitability and valuation metrics.
View details
V
Viji Finance Ltd
Viji Finance Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
View details
H
Hybrid Financial Services Ltd
Hybrid Financial Services Ltd shows potential but faces significant challenges in growth and profitability metrics.
View details
K
Kaushalya Infrastructure Development Corporation Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
H
Hawa Engineers Ltd
Hawa Engineers Ltd shows potential in a growing sector, but faces significant challenges in growth consistency, profitability, and valuation, making it a risky investment at this time.
View details
R
Ranjeet Mechatronics Ltd
Ranjeet Mechatronics Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
D
Dindigul Farm Product Ltd
Dindigul Farm Product Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
S
Soni Medicare Ltd
Soni Medicare Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
SVP Global Textiles Ltd
SVP Global Textiles Ltd faces significant challenges in growth and profitability, with risks outweighing potential rewards.
View details
P
PVV Infra Ltd
PVV Infra Ltd shows potential in a critical sector, but faces challenges in growth consistency and profitability metrics.
View details
T
Tatia Global Vennture Ltd
The stock presents several risks with limited growth prospects and profitability concerns, making it a risky investment.
View details
A
Akshar Spintex Ltd
Akshar Spintex Ltd presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns.
View details
S
Samsrita Labs Ltd
Samsrita Labs Ltd presents a mixed outlook with potential growth but significant risks and valuation concerns.
View details
S
Shubham Polyspin Ltd
Shubham Polyspin Ltd shows potential in a growing sector, but faces significant risks and inconsistencies in financial performance.
View details
Business Overview
The Nippon India Nifty Pharma ETF is a strategic investment vehicle designed for those looking to gain exposure to the Indian pharmaceutical sector. Ideal for both seasoned investors and newcomers, this ETF tracks the Nifty Pharma Index, offering a diversified portfolio of leading pharma companies. It matters because the healthcare sector is poised for growth, driven by innovation and increasing demand. This ETF provides a convenient way to invest in this dynamic market.
- Tracks the Nifty Pharma Index
- Diversified exposure to top pharma companies
- Ideal for both new and experienced investors
- Capitalizes on growth in the healthcare sector
- Low expense ratio compared to mutual funds
Investment Thesis
Nippon India Nifty Pharma ETF offers a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. This ETF is well-positioned to capitalize on the booming pharmaceutical sector in India.
- Backed by Nippon Life, a reputable and financially robust promoter group.
- Growing demand for digital healthcare services enhances long-term growth prospects.
- Attractive valuation metrics compared to other pharma ETFs in the market.
- Diversified exposure to leading pharmaceutical companies in India.
- Strong fundamentals support sustained performance in a growing sector.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare
- Strong pharmaceutical sector growth
- Diversification in investment portfolio
- Potential for long-term capital gains
Risks ⚠️
- Market volatility impacts returns
- Regulatory changes in healthcare
- Currency fluctuations affecting profits
- High competition in pharma sector
Peer Perspective
Nippon India Nifty Pharma ETF trades at a slight premium compared to peers like ICICI Prudential Pharma ETF and SBI Nifty Pharma ETF. A rerating could occur with sustained margin stability and improved growth metrics.
Future Outlook
Nippon India Nifty Pharma ETF is well-positioned to capitalize on the growing healthcare demand, provided that the sector maintains effective execution and cost control measures. This balance can drive sustained growth and investor confidence.
AI FAQs for Retail Users
- Q: What is Nippon India Nifty Pharma ETF?A: It is an exchange-traded fund that tracks the Nifty Pharma Index, representing pharmaceutical stocks.
- Q: How can I invest in this ETF?A: You can invest through a brokerage account that offers access to Indian stock exchanges.
- Q: What are the benefits of investing in this ETF?A: It provides exposure to the pharmaceutical sector with diversification and lower costs compared to individual stocks.
- Q: What is the expense ratio of this ETF?A: The expense ratio is the annual fee charged by the fund, typically lower than actively managed funds.
- Q: Is this ETF suitable for long-term investment?A: It may be suitable for long-term investors seeking exposure to the pharmaceutical sector, but consider your risk tolerance.
📊 Stock Investment Checklist (100 Points)
Nippon India Nifty Pharma ETF • Updated: 2025-09-17 05:51:51
-
10BusinessHighPharmaceutical sector is essential and growing, but faces regulatory challenges.
-
10GrowthHighModerate revenue growth observed, but profitability inconsistent across the sector.
-
10ProfitabilityHighROE and ROCE are average; cash flow is stable but not exceptional.
-
10ValuationHighValuation metrics are in line with peers, but growth potential is limited.
-
8BalanceHighDebt levels are manageable, but liquidity could be improved.
-
7GovernanceHighPromoter holding is decent, but some concerns about transparency.
-
10DriversHighPotential growth drivers exist, but execution risks are significant.
-
6TechnicalsGoodMarket sentiment is mixed; liquidity is moderate.
Final Score & Verdict
Score 48 / 100
• Decent
The Nippon India Nifty Pharma ETF shows potential in a growing sector but faces challenges in profitability and execution risks. It's a decent option for cautious investors.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 75/100